Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Professional Essentials · True Rheumatic Emergencies · Free · No registration

Diffuse alveolar hemorrhage & pulmonary–renal syndrome

Recognize lung hemorrhage early, investigate competing causes and keep anti-GBM, ANCA and lupus treatment pathways distinct.

Clinically reviewed: October 4, 2026 · Free to read · English

1. Recognize the respiratory emergency

Diffuse alveolar hemorrhage (DAH) is bleeding into the alveolar spaces. Pulmonary–renal syndrome combines lung hemorrhage with glomerular injury; it does not identify the underlying disease. Suspect DAH when acute breathlessness or hypoxemia, new bilateral opacities and an unexplained hemoglobin decline occur together. Hemoptysis may be absent, and the first hemoglobin measurement may be normal. Do not wait for the complete textbook presentation.

The immediate decision is where the patient can safely receive care. Suspected DAH warrants hospital assessment. Increasing oxygen requirements, exhaustion, altered consciousness or shock require critical-care escalation now. Record oxygen device and settings alongside saturation: an unchanged saturation achieved with substantially more support is deterioration. Outpatient serology or a scheduled CT must not delay transfer.

Inspect the whole phenotype: ENT inflammation, purpura, neuropathy, arthritis, lupus features and recent medication or exposure history. Urinalysis is essential even when creatinine is initially preserved. A nephritic sediment redirects assessment toward a pulmonary–renal process. The PEXIVAS DAH analysis illustrates the severity and heterogeneous renal involvement of this syndrome.

Recognition and atypical presentations → Professional access required

2. Investigate while stabilizing

Stabilize airway, breathing and circulation while obtaining a blood count, platelet count, serial hemoglobin, creatinine, electrolytes, coagulation studies, urinalysis and urine microscopy. Quantify urine protein and track urine output. Arrange blood grouping and compatibility testing when significant bleeding is possible. Portable chest imaging and bedside cardiac assessment can identify competing explanations without moving an unstable patient.

Send PR3-ANCA, MPO-ANCA and anti-GBM antibodies together when pulmonary–renal disease is plausible. Add ANA, anti-dsDNA and complement when lupus is suspected. Obtain blood cultures and targeted respiratory microbiology according to presentation and immunosuppression. Collect essential samples before immunotherapy or plasma exchange when immediately feasible, but sampling must not postpone rescue treatment.

Keep infection, hydrostatic edema, anticoagulant-related bleeding and thrombotic disease in the differential. Infection may coexist with immune capillaritis; fever does not settle attribution. Endocarditis can produce glomerulonephritis and positive ANCA. Review hydralazine, propylthiouracil and cocaine exposure. In systemic sclerosis, consider renal crisis with pulmonary edema before reflexively escalating glucocorticoids.

First assessment and competing causes → Professional access required

3. Confirm hemorrhage without creating delay

Bronchoscopy with sequential bronchoalveolar lavage can support alveolar hemorrhage and provide microbiological samples. Persistently or increasingly bloody returns from the same sampled region support DAH. Plan bronchoscopy with pulmonary and critical-care specialists because severe hypoxemia changes its risk. A bloody lavage does not establish an autoimmune cause.

Hemosiderin-containing macrophages support prior alveolar bleeding but may be absent early and are not independently specific. Similarly, ground-glass opacity is an imaging pattern shared by hemorrhage, infection, edema and other lung injury. Combine timing, physiology, lavage findings and the systemic assessment; avoid using one test as a substitute for the differential.

If glomerular disease is present, kidney biopsy may establish pauci-immune, anti-GBM or immune-complex injury and inform prognosis. Arrange tissue diagnosis promptly when safe. KDIGO advises that biopsy logistics should not delay treatment of a rapidly deteriorating presentation strongly compatible with ANCA vasculitis.

Confirmation and tissue diagnosis → Professional access required

4. Treat the cause and support failing organs

For organ-threatening ANCA-associated vasculitis, glucocorticoids with rituximab or cyclophosphamide provide remission induction. Drug selection depends on previous treatment, kidney function, infection risk, fertility and severity. The 2025 BSR recommendations reserve intravenous methylprednisolone pulses for selected organ-threatening presentations rather than routine administration to everyone. A steroid taper and infection-prevention plan belong with induction, not as later additions.

Strongly suspected anti-GBM disease requires urgent nephrology-led treatment, generally plasma exchange plus glucocorticoids and cyclophosphamide; do not wait for final confirmation in a compelling, deteriorating presentation. For lupus-associated hemorrhage, select immunosuppression with the lupus and organ teams while treating plausible infection in parallel.

Apply lung-protective ventilation when ARDS develops. ATS guidance supports limiting tidal volumes and inspiratory pressures, prone positioning in severe ARDS, and selected-patient consideration of venovenous ECMO. Active bleeding complicates extracorporeal support and requires specialist planning. Reversal or interruption of anticoagulation must reflect the actual agent, bleeding severity and thrombotic indication.

Do not present avacopan as an uncomplicated rescue option. FDA’s April 27, 2026 notice proposed withdrawal over efficacy-evidence concerns and highlighted serious liver injury; a proposal is not itself a completed withdrawal.

Etiology-specific treatment and safety → Professional access required

5. Keep plasma-exchange decisions separate

Anti-GBM disease and ANCA vasculitis have different exchange decisions. KDIGO anti-GBM guidance supports prompt exchange when indicated, continuing until circulating antibodies are undetectable. Double-positive ANCA/anti-GBM disease belongs initially in the anti-GBM pathway; ANCA positivity does not cancel that urgency.

For ANCA-associated DAH, plasma exchange is individualized. KDIGO advises considering it with hypoxemic hemorrhage and certain severe kidney presentations. BSR does not recommend routine exchange for pulmonary hemorrhage without severe renal involvement. In PEXIVAS, the DAH subgroup did not establish a definitive mortality benefit or absence of benefit; uncertainty is especially relevant in the most severe presentations. Discuss trajectory, concurrent kidney injury, infection risk and patient-specific burdens.

For life-threatening lupus vasculitis, including DAH, the 2025 ACR SLE guideline conditionally supports adding plasma exchange and/or IVIG to glucocorticoids and immunosuppression, on very-low-certainty evidence. This is a distinct recommendation, not an extrapolation from ANCA trials.

When exchange is selected, coordinate replacement fluid, coagulation monitoring and timing relative to rituximab or IVIG with the apheresis team. Procedure details should follow the disease-specific protocol and current bleeding status.

Plasma exchange: separate disease pathways → Professional access required

6. Reassess deterioration and plan recovery

Follow respiratory effort, oxygen support, circulation, hemoglobin, urine output and kidney function together. Falling inflammatory markers do not overrule worsening physiology. New fever, shock or infiltrates during induction should reopen the differential for infection, edema, thrombosis and toxicity before being labeled refractory vasculitis.

After stabilization, reconcile biopsy, serology and microbiology with the final diagnosis. Specify induction completion, steroid taper, monitoring and prophylaxis. Rituximab requires hepatitis B assessment and an appropriate prevention plan. ANCA vasculitis usually needs maintenance therapy; classic anti-GBM disease generally does not, whereas double-positive disease warrants an ANCA relapse-prevention assessment.

Antiphospholipid syndrome deserves particular attention because pulmonary microvascular injury and thrombosis may coexist with hemorrhage. An anticoagulant history therefore does not prove that excess anticoagulation caused the entire syndrome. The decision to interrupt, reverse or resume treatment needs joint hematology and critical-care input. Recurrent bleeding, a new thrombotic event or multiorgan deterioration may change that balance rapidly.

In a hospital without the required respiratory, renal or apheresis resources, establish transfer early. Name the accepting clinician and communicate which support can be maintained during transport; waiting for a send-away antibody assay should not become a transfer condition.

The handoff should state the respiratory trajectory, renal findings, samples pending, treatment doses and times, anticoagulant exposure, receiving team and next reassessment. Make worsening breathlessness, recurrent bleeding, fever and reduced urine output explicit triggers for urgent review.

Monitoring and care after stabilization → Professional access required

Selected sources

Clinical review: October 4, 2026. This independent overview accompanies the full professional emergency module.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Rheumatology